Setting your patients up for success
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.
Click here for Full Prescribing Information.
Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp;
Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry
eye disease: results of a phase III, randomized, double-masked,
(OPUS-3). Ophthalmology. 2017;124(1):53-60.